Evidence map›Paper›PMID 36968967›Full record

ArticleOpen forum infectious diseases2023

Excess Mortality Associated With Loiasis: Confirmation by a New Retrospective Cohort Study Conducted in the Republic of Congo.

Marlhand C Hemilembolo, Ange Clauvel Niama, Jérémy T Campillo, Sébastien D Pion, François Missamou, Charles Whittaker, Jean-Médard Kankou, Gilbert Ndziessi, Richard R Bileckot, Michel Boussinesq and 1 more

Full text read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Focal spleen lesions in loiasis: A pilot study in Gabon.PLoS neglected tropical diseases · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marlhand C HemilemboloUMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France.
Ange Clauvel NiamaMRC Centre for Global Infectious Disease Analysis, Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom.
Jérémy T CampilloUMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France.ORCID https://orcid.org/0000-0002-4400-5204
Sébastien D PionUMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France.
François MissamouProgramme National de Lutte contre l'Onchocercose, Direction de l'Épidémiologie et de la Lutte contre les Maladies, Ministère de la Santé et de la Population, Brazzaville, République du Congo.
Charles WhittakerMRC Centre for Global Infectious Disease Analysis, Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom.
Jean-Médard KankouProgramme National de Lutte contre l'Onchocercose, Direction de l'Épidémiologie et de la Lutte contre les Maladies, Ministère de la Santé et de la Population, Brazzaville, République du Congo.
Gilbert NdziessiFaculté des Sciences de la Santé, Université Marien-Ngouabi, Brazzaville, République du Congo.
Richard R BileckotFaculté des Sciences de la Santé, Université Marien-Ngouabi, Brazzaville, République du Congo.
Michel BoussinesqUMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France.
Cédric B ChesnaisUMI 233 TransVIHMI, Université de Montpellier, Institut de Recherche pour le Développement (IRD), INSERM Unité, Montpellier, France.ORCID https://orcid.org/0000-0002-8779-977X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Loiasis ( Methods: The cohort included 3329 individuals from 53 villages screened for loiasis in 2004. We compared mortality rates in 2021 for individuals initially diagnosed as with or without Results: At baseline, prevalence of microfilaremia was 16.2%. During 17.62 years of cohort follow-up, 751 deaths were recorded, representing a crude mortality rate of 15.36 (95% CI, 14.28-16.50) per 1000 person-years. Median survival time was 58.5 (95% CI, 49.7-67.3) years and 39.2 (95% CI, 32.6-45.8) years for amicrofilaremic and microfilaremic indiviudals, respectively. Conclusions: A significant reduction in life expectancy was associated with

Indexed as

cohort studyfilariasisloiasismortalityRepublic of Congo

Identifiers

PMID36968967
PMCPMC10034755

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read51
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.